CYRX · Cryoport, Inc.
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY26 earnings call · Aug 6, 2026TL;DR. Cryoport reported Q2 2026 revenue of $49.0 million, up 8% year-over-year, achieved positive adjusted EBITDA from continuing operations of $0.4 million, and is affirming full-year 2026 revenue guidance of $192 to $196 million despite macroeconomic/geopolitical uncertainties.
- + Net cash from operating activities improved by approximately $17 million in H1 2026 to about $5 million positive
- + Clinical trial count grew to a record 779 globally (net +51 YoY), with Phase 3 trials up to 94, supporting future commercial conversions
- − Total gross margin declined to 46.6% in Q2 2026 from 47.0% in Q2 2025
- − Management chose to affirm rather than raise full-year 2026 revenue guidance, citing geopolitical and macroeconomic uncertainties
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA for reportable segments non-GAAP | $5.94M | Three Months Ended June 30, 2026 filing | — |
| Adjusted EBITDA from continuing operations non-GAAP | -236K | Six Months Ended June 30, 2026 | — |
| Commercial Cell and Gene Therapy revenue (Life Sciences Services) | $9.4M | the three months ended June 30, 2026 filing | — |
| Life Sciences Products gross margin | 42.2% | the three months ended June 30, 2026 filing | — |
| Life Sciences Services gross margin | 49.9% | the three months ended June 30, 2026 filing | — |
| Number of supported commercially approved cell and gene therapies | 22 | As of June 30, 2026 | — |
| Number of supported global clinical trials | 779 | As of June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Integrated Freight & Logistics — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CYRX
this stock
Cryoport, Inc.
|
$886.87M | +89.0% | +12.4% | — | 5.5% |
|
UPS
United Parcel Service Inc
|
$79.94B | -6.1% | +8.2% | — | 3.0% |
|
FDX
Fedex Corp
|
$67.63B | — | +8.5% | 15.3 | 2.0% |
|
EXPD
Expeditors International Of Washington Inc
|
$24.37B | +30.3% | +13.5% | 27.3 | 3.4% |
|
JBHT
Hunt J B Transport Services Inc
|
$21.17B | +18.2% | +9.7% | 32.0 | 2.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CYRX | +4.4% | +14.7% | +82.3% | +4.3% | +89.0% |
| SPY | +1.2% | +0.6% | +11.6% | +1.6% | +13.6% |
| vs SPY | +3.2% | +14.1% | +70.7% | +2.7% | +75.3% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.